publication date: Jul. 2, 2020

NCI Trials

NCI Trials for July 2020

The National Cancer Institute approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10327

A Phase I Trial of  MLN0128 (Sapanisertib) and CB-839 HCL (Telaglenastat) in Advanced NSCLC Patients

City of Hope Comprehensive Cancer Center LAO

Riess, Jonathan W.

(916) 734-3772

 

Phase I – 10335

A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

Yale University Cancer Center LAO

Ratner, Lee

(314) 362-8836

 

Phase I – 10349

A Phase I Trial of the P97 Inhibitor CB-5339 in Patients with Advanced Solid Tumors and Lymphomas

National Cancer Institute LAO

Takebe, Naoko

(240) 781-3398

 

Phase I – 10388

A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Ohio State University Comprehensive Cancer Center LAO

Chauhan, Aman

(504) 278-0134

 

Phase II – 10211

A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

Yale University Cancer Center LAO

Berlin, Jordan D.

(615) 343-4128

 

Phase II – APEC1621N

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations

Children’s Oncology Group

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.